Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
ViroMissile, Inc.
AccSalus Biosciences, Inc.
JS InnoPharm, LLC
Mayo Clinic
Xencor, Inc.
Provectus Pharmaceuticals
Infinity Pharmaceuticals, Inc.
Fore Biotherapeutics
Virginia Commonwealth University
Merck Sharp & Dohme LLC
Yale University
Novartis
National Institutes of Health Clinical Center (CC)
Exelixis
Rutgers, The State University of New Jersey